Baxalta Inc (BXLT) : Dumont Blake Investment Advisors reduced its stake in Baxalta Inc by 0.72% during the most recent quarter end. The investment management company now holds a total of 16,741 shares of Baxalta Inc which is valued at $692,743 after selling 121 shares in Baxalta Inc , the firm said in a disclosure report filed with the SEC on Apr 21, 2016.Baxalta Inc makes up approximately 0.36% of Dumont Blake Investment Advisors’s portfolio.
Baxalta Inc closed down -0.42 points or -1.02% at $40.8 with 41,40,444 shares getting traded on Wednesday. Post opening the session at $41.03, the shares hit an intraday low of $40.69 and an intraday high of $41.25 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
Other Hedge Funds, Including , Seaward Management Limited Partnership reduced its stake in BXLT by selling 3,923 shares or 6.22% in the most recent quarter. The Hedge Fund company now holds 59,142 shares of BXLT which is valued at $2,447,296. Baxalta Inc makes up approx 0.13% of Seaward Management Limited Partnership’s portfolio.Umb Bank N Amo reduced its stake in BXLT by selling 2,940 shares or 13.36% in the most recent quarter. The Hedge Fund company now holds 19,067 shares of BXLT which is valued at $788,992. Baxalta Inc makes up approx 0.03% of Umb Bank N Amo’s portfolio.Exxonmobil Investment Management Inc Tx boosted its stake in BXLT in the latest quarter, The investment management firm added 44,204 additional shares and now holds a total of 165,866 shares of Baxalta Inc which is valued at $6,719,232. Baxalta Inc makes up approx 0.15% of Exxonmobil Investment Management Inc Tx’s portfolio. Pure Financial Advisors added BXLT to its portfolio by purchasing 7,320 company shares during the most recent quarter which is valued at $295,362. Baxalta Inc makes up approx 0.11% of Pure Financial Advisors’s portfolio.Livingston Group Asset Management Co (operating As Southp… boosted its stake in BXLT in the latest quarter, The investment management firm added 25 additional shares and now holds a total of 26,624 shares of Baxalta Inc which is valued at $1,074,278. Baxalta Inc makes up approx 0.70% of Livingston Group Asset Management Co (operating As Southp…’s portfolio.
On the company’s financial health, Baxalta Inc reported $0.57 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Feb 16, 2016. Analyst had a consensus of $0.55. The company had revenue of $1763.00 million for the quarter, compared to analysts expectations of $1712.08 million. The company’s revenue was up 4.8% compared to the same quarter last year.
Baxalta Incorporated is a biopharmaceutical company. The Company develops manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute medical conditions. The Company also focuses on disease areas including oncology as well as technology platforms including gene therapy and biosimilars. The Company has a portfolio of various therapies that address unmet medical needs across various disease areas including hemophilia immunology and oncology. The Company’s products include ADVATE RECOMBINATE HEMOFIL M Immunate Immunine PROTHROMPLEX TOTAL RIXUBIS FACTOR VII NF BEBULIN FEIBA OBIZUR GAMMAGARD LIQUID GAMMAGARD S/D Subcuvia HYQVIA FLEXBUMIN BUMINATE ARALAST NP GLASSIA NP CEPROTIN and ANTITHROMBIN III IMMUNO.